

CITATION REPORT

List of articles citing

Neoadjuvant Chemotherapy Switch in Borderline Resectable/Locally Advanced Pancreatic Cancer

DOI: 10.1245/s10434-021-10991-2
Annals of Surgical Oncology, 2021, , 1.

Source: <https://exaly.com/paper-pdf/118510073/citation-report.pdf>

Version: 2024-04-29

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
13	ASO Author Reflections: Neoadjuvant Chemotherapy Switch: Optimizing Neoadjuvant Treatment Sequencing in Pancreas Cancer. <i>Annals of Surgical Oncology</i> , 2021 , 1	3.1	
12	Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinoma: Role of the Radiologist and Oncologist in the Era of Precision Medicine. <i>Diagnostics</i> , 2021 , 11,	3.8	3
11	Short-Course or Total Neoadjuvant Chemotherapy in Resectable and Borderline Resectable Pancreatic Cancer - Current Status and Future Perspectives.. <i>Frontiers in Surgery</i> , 2022 , 9, 839339	2.3	0
10	Adaptive Dynamic Therapy and Survivorship for Operable Pancreatic Cancer. <i>JAMA Network Open</i> , 2022 , 5, e2218355	10.4	0
9	Neoadjuvant therapy in pancreatic cancer: a review and update on recent trials. 2022 , 38, 521-531		1
8	Cytoreduction with Hyperthermic Intraperitoneal Chemoperfusion for Pancreatic Cancer with Low-Volume Peritoneal Metastasis: Results from a Prospective Pilot Study.		
7	Pancreatic Adenocarcinoma Management.		4
6	FDG-PET Predicts Neoadjuvant Therapy Response and Survival in Borderline Resectable/Locally Advanced Pancreatic Adenocarcinoma. 2022 , 20, 1023-1032.e3		3
5	Tailoring Adjuvant Chemotherapy to Biologic Response Following Neoadjuvant Chemotherapy Impacts Overall Survival in Pancreatic Cancer.		0
4	Routine neoadjuvant chemotherapy for all patients with resectable pancreatic ductal adenocarcinoma? A review of the evidence. 2022 , 67, 102305		0
3	Tolerability, Attrition Rates, and Survival Outcomes of Neoadjuvant FOLFIRINOX for Non-Metastatic Pancreatic Adenocarcinoma: Intent-to-Treat Analysis. Publish Ahead of Print,		0
2	CA19-9 Response to First-Line Neoadjuvant FOLFIRINOX and Second-Line Gemcitabine/Nab-Paclitaxel for Patients with Operable Pancreatic Cancer. 2023 , 30, 3013-3021		0
1	Comprehensive multimodal management of borderline resectable pancreatic cancer: Current status and progress. 15, 142-162		0